AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29025134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis without cannabidiol
Number of subjects: 16
Study 29025134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis with cannabidiol
Number of subjects: 16
Study 29025134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (both types)
Number of subjects: 16
Study 29025134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 26332777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration group (VG) - trained using a ramp-up baseline with superimposed 30 Hz sinusoidal vibration
Number of subjects: 40
Study 26332777 — intervention group
Group type: COMPARATOR
Intervention: No-vibration group (NVG) - trained using the same baseline but without vibration
Number of subjects: 40
Study 26332777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell group (DG) - trained using dumbbells
Number of subjects: 40
Study 26332777 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - not trained
Number of subjects: 40
Study 25018142 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic control at 3 months (Group 1)
Number of subjects: 102
Study 25018142 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic control at 6 months (Group 2)
Number of subjects: 102
Study 25018142 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy with B blockers
Number of subjects: 102
Study 22459327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus healthy living skills
Number of subjects: 81
Study 22459327 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus affect regulation training
Number of subjects: 81
Study 19007927 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC) without contrast injection
Number of subjects: 300
Study 19007927 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulation with contrast injection
Number of subjects: 300
Study 17985004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus acetylsalicylic acid (ASA)
Number of subjects: 0
Study 17985004 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 0
Study 15364317 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune modulation therapy (IMT)
Number of subjects: 75
Study 15364317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11278160 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mcg transdermal estradiol
Number of subjects: 36
Study 11278160 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mcg transdermal estradiol
Number of subjects: 36
Study 11278160 — intervention group
Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 36
Study 9549810 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no Tamoxifen treatment)
Number of subjects: 4875
Study 8015795 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental dressing (chlortetracycline, aspirin, local anesthetics)
Number of subjects: 50
Study 8015795 — intervention group
Group type: COMPARATOR
Intervention: Control (no dressing)
Number of subjects: 50
Study 2563270 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (2 puffs, 400 micrograms)
Number of subjects: 10
Study 2563270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1257731 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-time treatment with corticosteroids and azathioprine
Number of subjects: 121
Study 1257731 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time treatment (as short as possible)
Number of subjects: 121
Study 1257731 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 121
Study 31164148 — intervention group
Group type: EXPERIMENTAL
Intervention: 540,000 IU cholecalciferol followed by monthly supplementation
Number of subjects: 410
Study 31164148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 410
Study 31164148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D oral supplementation
Number of subjects: 410
Study 28739541 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Advisor program (computer-based embodied conversational agent named 'Carmen')
Number of subjects: 0
Study 28739541 — intervention group
Group type: COMPARATOR
Intervention: Peer Advisors (trained human advisors)
Number of subjects: 0
Study 24939117 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable LED task lights
Number of subjects: 100
Study 24939117 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 22610590 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS + VI intervention
Number of subjects: 18
Study 21747329 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke alarm button test
Number of subjects: 0
Study 21747329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical smoke test
Number of subjects: 0
Study 18298197 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing unit
Number of subjects: 65
Study 18298197 — intervention group
Group type: COMPARATOR
Intervention: Halogen light
Number of subjects: 65
Study 16827769 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of 0.5% bupivacaine
Number of subjects: 85
Study 16827769 — intervention group
Group type: COMPARATOR
Intervention: 15 ml of 0.9% saline (control)
Number of subjects: 85
Study 15457989 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-gel alone
Number of subjects: 45
Study 15457989 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost alone
Number of subjects: 45
Study 15457989 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-gel and latanoprost in combination
Number of subjects: 45
Study 11506112 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 12
Study 11506112 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 12
Study 11506112 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 12
Study 11506112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9250102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (FOC; 41% eicosapentaenoic acid and 23% docosahexaenoic acid)
Number of subjects: 26
Study 9250102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil, OO)
Number of subjects: 26
Study 8282290 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg, increased to 10 mg if diastolic BP > 90 mmHg
Number of subjects: 89
Study 2941290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for five days
Number of subjects: 50
Study 2941290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31757656 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 921
Study 31757656 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 921
Study 29982690 — intervention group
Group type: COMPARATOR
Intervention: GSK2881078
Number of subjects: 0
Study 28277289 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty self‐management telephone intervention (SMI)
Number of subjects: 115
Study 28277289 — intervention group
Group type: COMPARATOR
Intervention: Liver disease education (LDE)
Number of subjects: 115
Study 26181037 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention plus usual care (n = 85)
Number of subjects: 171
Study 26181037 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 86)
Number of subjects: 171
Study 24022443 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting (WW)
Number of subjects: 254
Study 21382509 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 516
Study 21382509 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive recruitment of smokers in social networks
Number of subjects: 516
Study 21382509 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network members
Number of subjects: 516
Study 18320916 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (12 microg)
Number of subjects: 34
Study 18320916 — intervention group
Group type: COMPARATOR
Intervention: Albuterol nebulizer (2.5 mg)
Number of subjects: 34
Study 17036557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/d of valacyclovir for 60 days
Number of subjects: 152
Study 17036557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 15529837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics (7-day outpatient course)
Number of subjects: 0
Study 15529837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (7-day outpatient course)
Number of subjects: 0
Study 11414776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilisation technique
Number of subjects: 30
Study 9268953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 439
Study 9268953 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 439
Study 9268953 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 439
Study 8097215 — intervention group
Group type: COMPARATOR
Intervention: OpSite (traditional dressing)
Number of subjects: 101
Study 8097215 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite IV3000 (new dressing)
Number of subjects: 101
Study 3526609 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) treatment (6 ng/kg/min, n = 13)
Number of subjects: 26
Study 3526609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 26
Study 29805306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating hematological biomarkers and clinical characteristics for predicting overall survival (OS)
Number of subjects: 690
Study 29805306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 690
Study 29805306 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on total points (TPs) of the nomogram
Number of subjects: 690
Study 29805306 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent factors in the nomogram for OS
Number of subjects: 690
Study 27619215 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 139
Study 27619215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 139
Study 27619215 — intervention group
Group type: COMPARATOR
Intervention: Normal weight healthy reference group
Number of subjects: 139
Study 27619215 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 139
Study 24275010 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 37
Study 24275010 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 37
Study 23534179 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educative intervention
Number of subjects: 60
Study 23534179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 20484472 — intervention group
Group type: COMPARATOR
Intervention: hCG 0 IU
Number of subjects: 37
Study 20484472 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 15 IU
Number of subjects: 37
Study 20484472 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 60 IU
Number of subjects: 37
Study 20484472 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG 125 IU
Number of subjects: 37
Study 20484472 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel 7.5 g daily
Number of subjects: 37
Study 18777232 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety reduction imagery condition
Number of subjects: 60
Study 18777232 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety induction imagery condition
Number of subjects: 60
Study 18777232 — intervention group
Group type: COMPARATOR
Intervention: Jumping to conclusions (JTC) reasoning bias
Number of subjects: 60
Study 18777232 — intervention group
Group type: COMPARATOR
Intervention: JTC reasoning bias
Number of subjects: 60
Study 11848432 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture fixation to the scrotal wall
Number of subjects: 150
Study 11848432 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowing of the neck of the dartos pouch without fixation
Number of subjects: 150
Study 11848432 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture fixation with narrowing of the dartos fascial opening
Number of subjects: 150
Study 9759991 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 20 mg b.i.d. for 8 weeks (could be doubled once)
Number of subjects: 21
Study 9759991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9759991 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 21
Study 7936822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral content (BMC) supplementation
Number of subjects: 85
Study 7936822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 85
Study 3214383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel inserted for 6 hours
Number of subjects: 100
Study 3214383 — intervention group
Group type: COMPARATOR
Intervention: Laminaria tent inserted for 8 hours
Number of subjects: 100
Study 31686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (441 mg and 882 mg)
Number of subjects: 400
Study 31686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (441 mg)
Number of subjects: 400
Study 31686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (882 mg)
Number of subjects: 400
Study 31686823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 31686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil (pooled doses)
Number of subjects: 400
Study 31686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole lauroxil
Number of subjects: 400
Study 29279744 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-containing local hemostatics (TCLH)
Number of subjects: 274
Study 29279744 — intervention group
Group type: COMPARATOR
Intervention: No thrombin-containing local hemostatics (Control)
Number of subjects: 274
Study 25178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/day
Number of subjects: 116
Study 25178517 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg/day
Number of subjects: 116
Study 24054464 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to monotherapy
Number of subjects: 39
Study 21205110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-aspartate-hydrochloride (n = 27)
Number of subjects: 52
Study 21205110 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 25)
Number of subjects: 52
Study 18294180 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 postnatal home visits (Group A)
Number of subjects: 876
Study 18294180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 postnatal home visit (Group B)
Number of subjects: 876
Study 18294180 — intervention group
Group type: COMPARATOR
Intervention: No home visits (Group C)
Number of subjects: 876
Study 16648513 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional therapy only
Number of subjects: 0
Study 16648513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade tumors and/or lymphovascular invasion (LVI)
Number of subjects: 0
Study 16648513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic therapy
Number of subjects: 0
Study 16648513 — intervention group
Group type: EXPERIMENTAL
Intervention: Other T1a,bN0M0 cases
Number of subjects: 0
Study 12970132 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat yoghurt with correct information (HF-C)
Number of subjects: 15
Study 12970132 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat yoghurt with wrong information (LF-W)
Number of subjects: 15
Study 12970132 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat yoghurt (HF)
Number of subjects: 15
Study 12970132 — intervention group
Group type: COMPARATOR
Intervention: Low fat yoghurt (LF)
Number of subjects: 15
Study 11191541 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (2 microg kg(‐1) min(‐1))
Number of subjects: 328
Study 11191541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 9170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush after contrast injection
Number of subjects: 36
Study 9170041 — intervention group
Group type: COMPARATOR
Intervention: No saline flush after contrast injection
Number of subjects: 36
Study 9170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding
Number of subjects: 36
Study 9170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic parameters correlation
Number of subjects: 36
Study 9170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Image quality assessment
Number of subjects: 36
Study 1331788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation (1.2 g elemental calcium and 20 micrograms (800 IU) of vitamin D3 daily for 18 months)
Number of subjects: 3270
Study 1331788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 and calcium supplementation
Number of subjects: 3270
Study 1331788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study 31755300 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized meditation program (weekly classes for 2 years)
Number of subjects: 323
Study 31582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 54
Study 31582283 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus carboplatin
Number of subjects: 54
Study 31582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker analysis (IHC for 19 proteins, MGMT promoter methylation)
Number of subjects: 54
Study 31582283 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS) of poor and exceptional survivors
Number of subjects: 54
Study 29637421 — intervention group
Group type: EXPERIMENTAL
Intervention: POPS‐program (POtsdam Prevention at Schools)
Number of subjects: 1112
Study 29637421 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 1112
Study 26908041 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 % carbohydrate (L-CHO) beverages
Number of subjects: 13
Study 26908041 — intervention group
Group type: COMPARATOR
Intervention: 6 % carbohydrate (H-CHO) solutions with 20 g protein
Number of subjects: 13
Study 26908041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified training (IT)
Number of subjects: 13
Study 24503216 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromechanical training aid (Dynadjust™) used in year 4 of training
Number of subjects: 0
Study 24503216 — intervention group
Group type: COMPARATOR
Intervention: No Aid group (control)
Number of subjects: 0
Study 22188277 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjusting File (SAF) system
Number of subjects: 40
Study 22188277 — intervention group
Group type: COMPARATOR
Intervention: ProTaper rotary system
Number of subjects: 40
Study 20703975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate Active (BICARB A)
Number of subjects: 9
Study 20703975 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate Active (BICARB A) and Sodium bicarbonate Passive (BICARB P)
Number of subjects: 9
Study 17644545 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 342
Study 17644545 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-tumour necrosis factor-alpha infliximab
Number of subjects: 342
Study 17644545 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 342
Study 17644545 — intervention group
Group type: COMPARATOR
Intervention: Control group (other treatment strategies)
Number of subjects: 342
Study 16648739 — intervention group
Group type: EXPERIMENTAL
Intervention: OP‐1 Putty (3.5 mg OP‐1/g of collagen matrix per side)
Number of subjects: 19
Study 16648739 — intervention group
Group type: COMPARATOR
Intervention: Local autograft with HA‐TCP granules
Number of subjects: 19
Study 14631136 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 0.25 mg/kg
Number of subjects: 44
Study 14631136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10725817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) treatment for palmar psoriasis
Number of subjects: 12
Study 10725817 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current (IFC) treatment
Number of subjects: 12
Study 8840370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular fosphenytoin (480-1500 mg loading doses, 130-1250 mg daily maintenance doses for 3-14 days)
Number of subjects: 206
Study 8840370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin (1082 +/- 299 mg loading doses, 411 +/- 221 mg daily maintenance doses for 3-14 days)
Number of subjects: 206
Study 8840370 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenytoin sodium (1082 +/- 299 mg loading doses, 422 +/- 197 mg daily maintenance doses for 3-14 days)
Number of subjects: 206
Study 8840370 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous fosphenytoin and phenytoin sodium
Number of subjects: 206
Study 1628722 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 32
Study 1628722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6142005 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (intravenous administration)
Number of subjects: 12
Study 31343440 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 120 mg, administered as a monthly subcutaneous injection for 52 weeks.
Number of subjects: 500
Study 29023683 — intervention group
Group type: EXPERIMENTAL
Intervention: Child group
Number of subjects: 126
Study 29023683 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child group
Number of subjects: 126
Study 29023683 — intervention group
Group type: COMPARATOR
Intervention: Parent group
Number of subjects: 126